Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Loading
Home
News
Introducing Valthos

From Valthos Blog

By

October 24, 2025

Introducing Valthos

Introducing Valthos
Valthos builds next-generation biodefense. As AI advances, life itself has become programmable. The world is approaching near-universal access to powerful, dual-use biotechnologies capable of eliminating disease or creating it. Today, it's faster to weaponize biology than to advance new cures. Valthos equips experts in government and life sciences with powerful tools that can, for the first time, update medical countermeasures to match the speed of the threats we face. We envision a future where any threat to human health can be immediately identified and neutralized, whether the origin is external or within our own bodies. We build AI systems to rapidly characterize biological sequences and update medicines in real time. We raised $30 million from the OpenAI Startup Fund, Lux Capital, and Founders Fund to scale this infrastructure for government and life sciences stakeholders. Our founding team comes from Palantir, DeepMind, the Broad Institute, and the Arc Institute, and we're hiring exceptional people to join us in this mission.

View original article on valthos.com

Most Recent

With EU backing, QuantumDiamonds aims to speed up chip manufacturing

With EU backing, QuantumDiamonds aims to speed up chip manufacturing

Like its U.S. counterpart, the European Chips Act aims to foster the semiconductor industry — in part thanks to state subsidies. One of the beneficiaries is QuantumDiamonds, a German startup that applies a novel approach to inspecting chips.

Jul 8, 2026

Why this CEO thinks video games make better training data than the internet

Why this CEO thinks video games make better training data than the internet

Watch as General Intuition CEO Pim de Witt joins TechCrunch's Equity podcast to explain how the startup's $320M round and gaming data are powering the next wave of physical AI and robotics.

Jul 8, 2026

Crypto VC firm Paradigm raises $1.2B to invest in ‘technical frontier’ startups

Crypto VC firm Paradigm raises $1.2B to invest in ‘technical frontier’ startups

For Paradigm, the technical frontier will stretch beyond its cryptocurrency investment roots. This fund is expected to expand its investment focus to include robotics and AI.

Jul 8, 2026

Prime Intellect raises $130M Series A to help enterprises build their own AI agents

Prime Intellect raises $130M Series A to help enterprises build their own AI agents

Founded in 2024, Prime Intellect’s goal is to give organizations capabilities to train their own agentic systems without relying on frontier AI labs.

Jul 8, 2026

Similar Posts

Valthos Raises $30M From OpenAI, Lux Capital, and Founders Fund to Build Next Generation Biodefense

Valthos Raises $30M From OpenAI, Lux Capital, and Founders Fund to Build Next Generation Biodefense

Valthos announced $30 million in seed financing led by OpenAI Startup Fund, Lux Capital, and Founders Fund to support the development of next-generation biodefense systems.

Oct 28, 2025

Valthos Secures $30M Seed Funding for AI Biodefense

Valthos Secures $30M Seed Funding for AI Biodefense

Biodefense company Valthos announced it has closed $30 million in seed financing led by OpenAI Startup Fund, Lux Capital and Founders Fund to support AI systems for biological threat detection.

Nov 2, 2025

AI Biodefense Startup Valthos Launches With $30 Million, OpenAI Backing

AI Biodefense Startup Valthos Launches With $30 Million, OpenAI Backing

Biodefense startup Valthos emerged from stealth with $30 million in funding backed by OpenAI to develop AI systems that detect and counter biological threats in real time.

Oct 24, 2025

Hippocratic is building a large language model for healthcare

Hippocratic is building a large language model for healthcare

AI, specifically generative AI, has the potential to transform healthcare. At least, that sales pitch from Hippocratic Health, which emerged from stealth today with a whopping $50 million in seed financing behind it and a valuation in the “triple digit millions.” The tranche, co-led by General Catalyst and Andreessen Horowitz, is a big vote of […]

May 16, 2023

Most Recent

With EU backing, QuantumDiamonds aims to speed up chip manufacturing

With EU backing, QuantumDiamonds aims to speed up chip manufacturing

Like its U.S. counterpart, the European Chips Act aims to foster the semiconductor industry — in part thanks to state subsidies. One of the beneficiaries is QuantumDiamonds, a German startup that applies a novel approach to inspecting chips.

Jul 8, 2026

Why this CEO thinks video games make better training data than the internet

Why this CEO thinks video games make better training data than the internet

Watch as General Intuition CEO Pim de Witt joins TechCrunch's Equity podcast to explain how the startup's $320M round and gaming data are powering the next wave of physical AI and robotics.

Jul 8, 2026

Crypto VC firm Paradigm raises $1.2B to invest in ‘technical frontier’ startups

Crypto VC firm Paradigm raises $1.2B to invest in ‘technical frontier’ startups

For Paradigm, the technical frontier will stretch beyond its cryptocurrency investment roots. This fund is expected to expand its investment focus to include robotics and AI.

Jul 8, 2026

Prime Intellect raises $130M Series A to help enterprises build their own AI agents

Prime Intellect raises $130M Series A to help enterprises build their own AI agents

Founded in 2024, Prime Intellect’s goal is to give organizations capabilities to train their own agentic systems without relying on frontier AI labs.

Jul 8, 2026

Similar Posts

Valthos Raises $30M From OpenAI, Lux Capital, and Founders Fund to Build Next Generation Biodefense

Valthos Raises $30M From OpenAI, Lux Capital, and Founders Fund to Build Next Generation Biodefense

Valthos announced $30 million in seed financing led by OpenAI Startup Fund, Lux Capital, and Founders Fund to support the development of next-generation biodefense systems.

Oct 28, 2025

Valthos Secures $30M Seed Funding for AI Biodefense

Valthos Secures $30M Seed Funding for AI Biodefense

Biodefense company Valthos announced it has closed $30 million in seed financing led by OpenAI Startup Fund, Lux Capital and Founders Fund to support AI systems for biological threat detection.

Nov 2, 2025

AI Biodefense Startup Valthos Launches With $30 Million, OpenAI Backing

AI Biodefense Startup Valthos Launches With $30 Million, OpenAI Backing

Biodefense startup Valthos emerged from stealth with $30 million in funding backed by OpenAI to develop AI systems that detect and counter biological threats in real time.

Oct 24, 2025

Hippocratic is building a large language model for healthcare

Hippocratic is building a large language model for healthcare

AI, specifically generative AI, has the potential to transform healthcare. At least, that sales pitch from Hippocratic Health, which emerged from stealth today with a whopping $50 million in seed financing behind it and a valuation in the “triple digit millions.” The tranche, co-led by General Catalyst and Andreessen Horowitz, is a big vote of […]

May 16, 2023